Abstract
Conroy et al. (May 12 issue)1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine. It has been debated whether gemcitabine-based combination therapies provide any additional benefit, and meta-analyses have reached conflicting conclusions.2-4 A sensitivity analysis of data pooled from seven randomized trials involving 2422 patients in which single-agent gemcitabine was compared with gemcitabine in combination with cisplatin, oxaliplatin, or capecitabine indicates that the use of gemcitabine-based doublets had a clinically negligible, although statistically significant, absolute survival benefit ( Table 1 ). However, power calculations reliably (80% power, two-tailed alpha of 0.05) rule out the possibility that gemcitabine-based doublets could improve 1-year survival by more than 5%. In that respect, the results of the FOLFIRINOX study strongly suggest that moving away from using gemcitabine alone versus using gemcitabine-based combinations is actually a wiser, more creative, and more effective strategy to improve outcomes in patients with advanced pancreatic cancer. In addition, trials of such combination chemotherapy regimens could foster the development of molecularly targeted agents in this disease.5